Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT05169489
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05164250
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇪🇸
Hospital Clínico Universitario de Santiago, Santiago, A Coruña, Spain
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT05133531
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇮🇳Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus, New Delhi, Delhi, India
🇮🇳Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, Punjab, India
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05131204
- Locations
- 🇺🇸
Regeneron Research Facility, Whittier, California, United States
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 370
- Registration Number
- NCT05125016
- Locations
- 🇺🇸
Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Stanford University Medical Center - Blake Wilbur Drive, Palo Alto, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Other: Noninterventional
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT05106387
- Locations
- 🇺🇸
Connie Frank Transplant Center at UCSF, San Francisco, California, United States
🇺🇸Yale University of Medicine, New Haven, Connecticut, United States
🇺🇸Comprehensive Transplant Center, Chicago, Illinois, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT05102136
- Locations
- 🇧🇪
Regeneron Study Site, Edegem, Antwerp, Belgium
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT05092347
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Connie Frank Transplant Center at UCSF, San Francisco, California, United States
COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: casirivimab+imdevimab
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05092581
- Locations
- 🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇺🇸State University of New York at Stony Brook, Stony Brook, New York, United States